Perkinelmer (PKI) 55.91 $PKI
Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 61.02 (-0.04), GLYC: 8.50 (-0.34), PKI: 55.91 (-0.78), HUM: 169.57 (-1.61)
PerkinElmer Elects Frank Witney to Board of Directors
BusinessWire - Wed Jul 27, 3:15PM CDT
PerkinElmer, Inc. (NYSE
KI), a global leader focused on improving the health and safety of people and the environment, today announced that Frank Witney, Ph.D., has been elected to the Company's Board of Directors.
PKI: 55.91 (-0.78)
PerkinElmer Board Declares Quarterly Dividend
BusinessWire - Wed Jul 27, 3:15PM CDT
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on July 27, 2016. This dividend is payable on November 10, 2016 to all shareholders of record at the close of business on October 14, 2016.
PKI: 55.91 (-0.78)
Zacks.com featured highlights: CoStar Group, Curtiss-Wright, Healthsouth, Inogen and PerkinElmer
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:30AM CDT
Zacks.com featured highlights: CoStar Group, Curtiss-Wright, Healthsouth, Inogen and PerkinElmer
CSGP: 204.82 (-0.58), CW: 88.02 (-1.01), INGN: 52.74 (-0.26), HLS: 41.60 (-0.45), PKI: 55.91 (-0.78)
Look for Shares of PerkinElmer to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Wed Jul 13, 1:43PM CDT
PerkinElmer (NYSEKI) traded in a range yesterday that spanned from a low of $54.85 to a high of $55.52. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $54.92 on volume of 295,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PKI: 55.91 (-0.78)
PerkinElmer Webinar on Using Multiplexed IHC to Decipher Clues in the Immunological Microenvironment of Cancer
PRWeb - Tue Jul 12, 6:06PM CDT
Cancer therapies such as ipilimumab and nivolumab have shown promise in therapeutic approaches directing a patient's immune system to attack his or her own tumors. Further progress will necessitate a precise understanding of the tumor microenvironment, characterization of the location and status of immune cells, and their interaction with tumor cells. This will require methods that provide phenotyping of immune and cancer cells, combined with the cytoarchitectonics of the tumor.
PKI: 55.91 (-0.78)
PerkinElmer Prices Offering of Euro-Denominated Senior Notes
BusinessWire - Tue Jul 12, 3:15PM CDT
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, announced today that it has priced an offering of EUR500 million aggregate principal amount of 1.875% Senior Notes due 2026 at an issue price of 99.118% of the principal amount.
PKI: 55.91 (-0.78)
PerkinElmer To Hold Earnings Call on Thursday, August 4, 2016
BusinessWire - Fri Jul 08, 3:15PM CDT
PerkinElmer, Inc., (NYSEKI) a global leader focused on improving the health and safety of people and the environment, today announced that on Thursday, August 4, 2016, after market close, the Company will release second quarter 2016 results. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Robert F. Friel, chairman and chief executive officer, and Andy Wilson, senior vice president and chief financial officer, will host the conference call.
PKI: 55.91 (-0.78)
John L. Stauch Elected to Deluxe Corporation Board of Directors; Mary Ann O'Dwyer Resigns from Board
BusinessWire - Fri Jul 08, 7:47AM CDT
Deluxe Corporation (NYSE: DLX) announced the election of John L. Stauch to its Board of Directors effective July 7, 2016.
PNR: 61.13 (-1.16), DLX: 67.67 (+0.18), PKI: 55.91 (-0.78)
Gyros Protein Technologies Appoints Frank Witney as Chairman
BusinessWire - Wed Jun 22, 8:47AM CDT
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the appointment of Dr. Frank Witney as Chairman of the Board. Dr. Witney's appointment is a key milestone in Gyros Protein Technologies' strategy to build upon the Company's strong market position through ongoing development of innovative products, commercial expansion, and growth via acquisition. David Patteson, prior chairman of Protein Technologies, Inc. remains as a Director.
PKI: 55.91 (-0.78)
PerkinElmer, Inc. (PKI) - Product Pipeline Market Analysis Report by Radiant Insights
GlobeNewswire - Wed Jun 22, 6:39AM CDT
PerkinElmer, Inc. (PerkinElmer) is a provider of detection, imaging, and informatics solutions and services to diagnostics, research, laboratory services, environmental, and industrial markets. The company's product portfolio comprises lab products and services; imaging components; diagnostic services for clinicians and families; and cord blood and tissue banking services. It also offers technologies for detection and identification of disease, contaminants, and biological pathways; imaging technologies for recording biological, cellular, and treatment events; and software platforms and informatics for data management, visualization, analytics, efficient workflow. PerkinElmer's products find applications in early detection of genetic disorders, infectious disease testing, diagnosis of metabolic disorders, cancer treatment, drug discovery and other research activities. Its service offerings include analytics, compliance, contract research, custom research, genetic screening, instrumentation, prenatal screening, information, and scientific services.
PKI: 55.91 (-0.78)
NuGEN Technologies Appoints New CEO
BusinessWire - Tue Jun 14, 5:00AM CDT
NuGEN Technologies, Inc. today announced the appointment of Nitin Sood as Chief Executive Officer. He succeeds Elizabeth Hutt who recently left to pursue another opportunity.
PKI: 55.91 (-0.78)
PerkinElmer and Sofie Biosciences extend and expand partnership
PR Newswire - Fri Jun 10, 3:00PM CDT
SOFIE BIOSCIENCES, a molecular imaging company, and PerkinElmer, a global leader in the life sciences, are pleased to announce a multi-year extension of their existing partnership to deliver preclinical in vivo imaging tools for positron emission tomography (PET). PET is a non-invasive, translational imaging technology that quantitatively and safely measures the biology of disease.
PKI: 55.91 (-0.78)
Premarket Research Report Covering the Medical Laboratories & Research Industry
ACCESSWIRE - Thu Jun 09, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 9, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Laboratories & Research industry. Companies recently under review include Thermo Fisher Scientific, Great Basin Scientific, PerkinElmer, and Organovo. Register with us now for your free membership and see our complete reports on these equities at:
GBSN: 0.34 (-0.12), TMO: 156.44 (-3.12), ONVO: 4.25 (-0.12), PKI: 55.91 (-0.78)
PerkinElmer Webinar on Rethinking Timeline for Quality by Design Studies in Protein Process Development
PRWeb - Wed Jun 01, 2:21PM CDT
A perpetual challenge is posed by improving systems for rapid small-scale protein purification and analysis used to acquire sample numbers for statistically significant analyses needed for the selection of lead candidate molecules.
PKI: 55.91 (-0.78)
PerkinElmer Opens Customer Knowledge Center in Taiwan
BusinessWire - Fri May 27, 12:00AM CDT
PerkinElmer, Inc. held an opening ceremony for its new Taipei Customer Knowledge Center (CKC) located in Neihu District, Taipei City on May 27. President of PerkinElmer's Environmental Health business, Jon DiVincenzo, as well as Vice President and General Manager of Global Sales and Service, Nam-Hoon Kim, hosted more than 70 guests from the environmental, chemicals and semiconductor testing industries and academia, along with PerkinElmer representatives from the Asia-Pacific region.
PKI: 55.91 (-0.78)
Waters Corp. Expands Xevo Line with Xevo TQ-XS Launch
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:44AM CDT
Waters Corporation (WAT) expanded its portfolio of Xevo mass spectrometers with the launch of Xevo TQ-XS mass spectrometer, which is arguably the most sensitive instrument of its kind in the market.
BEAT: 19.50 (+0.31), BRKR: 24.72 (-0.09), PKI: 55.91 (-0.78), WAT: 157.21 (-2.37)
LABWORKS LIMS Acquired from PerkinElmer by Labworks LLC - Future Never Looked Brighter
BusinessWire - Wed May 11, 7:00AM CDT
Labworks, LLC, the industry's choice for robust yet simple solutions for Laboratory Information Management Systems (LIMS), announced that it has acquired the LABWORKS LIMS product line from PerkinElmer Health Sciences. The LABWORKS LIMS product line, which has a 25-year history of LIMS excellence, was purchased by Labworks, LLC, which is comprised of seasoned software executives and many previous PerkinElmer/LABWORKS employees, many of whom have over 20 years of experience supporting LABWORKS LIMS and its 300+ customer base.
PKI: 55.91 (-0.78)
Moving Average Crossover Alert: PerkinElmer (PKI)
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:38AM CDT
PerkinElmer Inc. (PKI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
PKI: 55.91 (-0.78)
PerkinElmer to Present at UBS Global Healthcare Conference
BusinessWire - Mon May 09, 3:15PM CDT
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 1:00 pm ET at the Grand Hyatt New York.
PKI: 55.91 (-0.78)
Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 61.02 (-0.04), GLYC: 8.50 (-0.34), PKI: 55.91 (-0.78), HUM: 169.57 (-1.61)
PerkinElmer Elects Frank Witney to Board of Directors
BusinessWire - Wed Jul 27, 3:15PM CDT
PerkinElmer, Inc. (NYSE
KI), a global leader focused on improving the health and safety of people and the environment, today announced that Frank Witney, Ph.D., has been elected to the Company's Board of Directors. PKI: 55.91 (-0.78)
PerkinElmer Board Declares Quarterly Dividend
BusinessWire - Wed Jul 27, 3:15PM CDT
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on July 27, 2016. This dividend is payable on November 10, 2016 to all shareholders of record at the close of business on October 14, 2016.
PKI: 55.91 (-0.78)
Zacks.com featured highlights: CoStar Group, Curtiss-Wright, Healthsouth, Inogen and PerkinElmer
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:30AM CDT
Zacks.com featured highlights: CoStar Group, Curtiss-Wright, Healthsouth, Inogen and PerkinElmer
CSGP: 204.82 (-0.58), CW: 88.02 (-1.01), INGN: 52.74 (-0.26), HLS: 41.60 (-0.45), PKI: 55.91 (-0.78)
Look for Shares of PerkinElmer to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Wed Jul 13, 1:43PM CDT
PerkinElmer (NYSE
KI) traded in a range yesterday that spanned from a low of $54.85 to a high of $55.52. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $54.92 on volume of 295,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PKI: 55.91 (-0.78)
PerkinElmer Webinar on Using Multiplexed IHC to Decipher Clues in the Immunological Microenvironment of Cancer
PRWeb - Tue Jul 12, 6:06PM CDT
Cancer therapies such as ipilimumab and nivolumab have shown promise in therapeutic approaches directing a patient's immune system to attack his or her own tumors. Further progress will necessitate a precise understanding of the tumor microenvironment, characterization of the location and status of immune cells, and their interaction with tumor cells. This will require methods that provide phenotyping of immune and cancer cells, combined with the cytoarchitectonics of the tumor.
PKI: 55.91 (-0.78)
PerkinElmer Prices Offering of Euro-Denominated Senior Notes
BusinessWire - Tue Jul 12, 3:15PM CDT
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, announced today that it has priced an offering of EUR500 million aggregate principal amount of 1.875% Senior Notes due 2026 at an issue price of 99.118% of the principal amount.
PKI: 55.91 (-0.78)
PerkinElmer To Hold Earnings Call on Thursday, August 4, 2016
BusinessWire - Fri Jul 08, 3:15PM CDT
PerkinElmer, Inc., (NYSE
KI) a global leader focused on improving the health and safety of people and the environment, today announced that on Thursday, August 4, 2016, after market close, the Company will release second quarter 2016 results. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Robert F. Friel, chairman and chief executive officer, and Andy Wilson, senior vice president and chief financial officer, will host the conference call. PKI: 55.91 (-0.78)
John L. Stauch Elected to Deluxe Corporation Board of Directors; Mary Ann O'Dwyer Resigns from Board
BusinessWire - Fri Jul 08, 7:47AM CDT
Deluxe Corporation (NYSE: DLX) announced the election of John L. Stauch to its Board of Directors effective July 7, 2016.
PNR: 61.13 (-1.16), DLX: 67.67 (+0.18), PKI: 55.91 (-0.78)
Gyros Protein Technologies Appoints Frank Witney as Chairman
BusinessWire - Wed Jun 22, 8:47AM CDT
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the appointment of Dr. Frank Witney as Chairman of the Board. Dr. Witney's appointment is a key milestone in Gyros Protein Technologies' strategy to build upon the Company's strong market position through ongoing development of innovative products, commercial expansion, and growth via acquisition. David Patteson, prior chairman of Protein Technologies, Inc. remains as a Director.
PKI: 55.91 (-0.78)
PerkinElmer, Inc. (PKI) - Product Pipeline Market Analysis Report by Radiant Insights
GlobeNewswire - Wed Jun 22, 6:39AM CDT
PerkinElmer, Inc. (PerkinElmer) is a provider of detection, imaging, and informatics solutions and services to diagnostics, research, laboratory services, environmental, and industrial markets. The company's product portfolio comprises lab products and services; imaging components; diagnostic services for clinicians and families; and cord blood and tissue banking services. It also offers technologies for detection and identification of disease, contaminants, and biological pathways; imaging technologies for recording biological, cellular, and treatment events; and software platforms and informatics for data management, visualization, analytics, efficient workflow. PerkinElmer's products find applications in early detection of genetic disorders, infectious disease testing, diagnosis of metabolic disorders, cancer treatment, drug discovery and other research activities. Its service offerings include analytics, compliance, contract research, custom research, genetic screening, instrumentation, prenatal screening, information, and scientific services.
PKI: 55.91 (-0.78)
NuGEN Technologies Appoints New CEO
BusinessWire - Tue Jun 14, 5:00AM CDT
NuGEN Technologies, Inc. today announced the appointment of Nitin Sood as Chief Executive Officer. He succeeds Elizabeth Hutt who recently left to pursue another opportunity.
PKI: 55.91 (-0.78)
PerkinElmer and Sofie Biosciences extend and expand partnership
PR Newswire - Fri Jun 10, 3:00PM CDT
SOFIE BIOSCIENCES, a molecular imaging company, and PerkinElmer, a global leader in the life sciences, are pleased to announce a multi-year extension of their existing partnership to deliver preclinical in vivo imaging tools for positron emission tomography (PET). PET is a non-invasive, translational imaging technology that quantitatively and safely measures the biology of disease.
PKI: 55.91 (-0.78)
Premarket Research Report Covering the Medical Laboratories & Research Industry
ACCESSWIRE - Thu Jun 09, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 9, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Laboratories & Research industry. Companies recently under review include Thermo Fisher Scientific, Great Basin Scientific, PerkinElmer, and Organovo. Register with us now for your free membership and see our complete reports on these equities at:
GBSN: 0.34 (-0.12), TMO: 156.44 (-3.12), ONVO: 4.25 (-0.12), PKI: 55.91 (-0.78)
PerkinElmer Webinar on Rethinking Timeline for Quality by Design Studies in Protein Process Development
PRWeb - Wed Jun 01, 2:21PM CDT
A perpetual challenge is posed by improving systems for rapid small-scale protein purification and analysis used to acquire sample numbers for statistically significant analyses needed for the selection of lead candidate molecules.
PKI: 55.91 (-0.78)
PerkinElmer Opens Customer Knowledge Center in Taiwan
BusinessWire - Fri May 27, 12:00AM CDT
PerkinElmer, Inc. held an opening ceremony for its new Taipei Customer Knowledge Center (CKC) located in Neihu District, Taipei City on May 27. President of PerkinElmer's Environmental Health business, Jon DiVincenzo, as well as Vice President and General Manager of Global Sales and Service, Nam-Hoon Kim, hosted more than 70 guests from the environmental, chemicals and semiconductor testing industries and academia, along with PerkinElmer representatives from the Asia-Pacific region.
PKI: 55.91 (-0.78)
Waters Corp. Expands Xevo Line with Xevo TQ-XS Launch
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:44AM CDT
Waters Corporation (WAT) expanded its portfolio of Xevo mass spectrometers with the launch of Xevo TQ-XS mass spectrometer, which is arguably the most sensitive instrument of its kind in the market.
BEAT: 19.50 (+0.31), BRKR: 24.72 (-0.09), PKI: 55.91 (-0.78), WAT: 157.21 (-2.37)
LABWORKS LIMS Acquired from PerkinElmer by Labworks LLC - Future Never Looked Brighter
BusinessWire - Wed May 11, 7:00AM CDT
Labworks, LLC, the industry's choice for robust yet simple solutions for Laboratory Information Management Systems (LIMS), announced that it has acquired the LABWORKS LIMS product line from PerkinElmer Health Sciences. The LABWORKS LIMS product line, which has a 25-year history of LIMS excellence, was purchased by Labworks, LLC, which is comprised of seasoned software executives and many previous PerkinElmer/LABWORKS employees, many of whom have over 20 years of experience supporting LABWORKS LIMS and its 300+ customer base.
PKI: 55.91 (-0.78)
Moving Average Crossover Alert: PerkinElmer (PKI)
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:38AM CDT
PerkinElmer Inc. (PKI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
PKI: 55.91 (-0.78)
PerkinElmer to Present at UBS Global Healthcare Conference
BusinessWire - Mon May 09, 3:15PM CDT
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 1:00 pm ET at the Grand Hyatt New York.
PKI: 55.91 (-0.78)
